10:41 AM EST, 03/06/2024 (MT Newswires) -- Abbott Laboratories ( ABT ) said Wednesday that real-world data from two studies showed that people with Type 2 diabetes using GLP-1 medicines and the company's FreeStyle Libre technology, a continuous glucose monitoring system, can achieve greater improvement in their blood glucose levels compared with therapy using GLP-1 medicines alone.

One of the studies showed that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1c six months after adding FreeStyle Libre technology to their treatment, the company said. HbA1c is a blood test that measures a person's average blood glucose level over three months.

The other study showed people with Type 2 diabetes saw a 2.4% reduction in HbA1c when using GLP-1 medicines along with FreeStyle Libre technology, compared with a 1.7% reduction when using GLP-1 alone, the company said.

Price: 119.26, Change: +0.78, Percent Change: +0.66